New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression
oncodaily.com/oncolibrary/...
#ASCO #Cancer #CancerCare #CancerResearch #Headlines #JCO #JCOOncology #Practice #NewPaperAlert #Medicine #Health
oncodaily.com/oncolibrary/...
#ASCO #Cancer #CancerCare #CancerResearch #Headlines #JCO #JCOOncology #Practice #NewPaperAlert #Medicine #Health
New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression - OncoDaily
Meta-analysis on post-CDK4/6 inhibitor treatment for HR+ breast cancer, revealing how continuing or switching CDK4/6 inhibitors boosts survival.
oncodaily.com
December 26, 2024 at 8:39 PM
New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression
oncodaily.com/oncolibrary/...
#ASCO #Cancer #CancerCare #CancerResearch #Headlines #JCO #JCOOncology #Practice #NewPaperAlert #Medicine #Health
oncodaily.com/oncolibrary/...
#ASCO #Cancer #CancerCare #CancerResearch #Headlines #JCO #JCOOncology #Practice #NewPaperAlert #Medicine #Health